Christopher James Stevens - 11 Feb 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Chief Operating Officer
Issuer ticker: RCKT
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:05:20 UTC
Prior SEC filing: 06 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens

Key filing fact

Christopher James Stevens filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 13 Feb 2026.

Key facts

This page summarizes Christopher James Stevens's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 06 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002079768 Primary reporting owner

Stevens Christopher James

Relationship: Chief Operating Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value: $0
Shares: +61,963
Change %: +15%
Price: $0.000000
Shares after: 469,129
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +93,037
Change %
Price: $0.000000
Shares after: 93,037
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,037
Exercise price: $3.24
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Footnote F2

Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

Footnote F3

This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.